Amongst these successful stories of targeted agents is the BCR-ABL kinase inhibitor imatinib (Gleevec; Novartis), which is using for the treatment of chronic myelogenous leukemia (CML). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.